What factor should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?

Haemophilia

Volumn 7, Issue 1, 2001, Pages 99-102

  Petrini, P ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Haemophilia; Prophylaxis; Trough level

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; EMLA; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

ARTHROPATHY; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DISEASE SEVERITY; DOSE RESPONSE; FREQUENCY ANALYSIS; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MALE; PERIPHERAL VEIN; PRIORITY JOURNAL; PROPHYLAXIS; VASCULAR ACCESS; DECISION MAKING; INFANT; PRESCHOOL CHILD;

CHILD, PRESCHOOL; DECISION MAKING; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; INFANT;

EID: 0034746292     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2001.00471.x     Document Type: Article

References (12)

1. Prophylaxis with factor concentrates in preventing hemophilic arthopathy
2. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B
3. A longitudinal study of orthopaedic outcomes for severe factor VIII-deficient hemophiliacs
4. Hemophilia prophylaxis in young patients: A long-term follow up
5. Implantable central venous catheters facilitate prophylactic treatment in children with haemophilia
6. Central venous access catheters in children with haemophilia
7. The impact of prophylactic treatment on children with severe haemophilia
8. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized
9. Results of secondary prophylaxis in children with severe haemophilia
10. Methods of haemophilia care delivery: Regular prophylaxis versus episodic treatment
11. Hemophilia A prophylaxis with factor VIII concentrate in a home-treatment program: A controlled study
12. Improved cost-effectiveness by pharmaco-kinetic dosing of factor VIII in prophylactic treatment of haemophilia A